Eva Sedláčková

Slovak Academy of Sciences — SK

Medicine · Health Sciences

12h-index3.9kcitations104works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroendocrine Tumor Research Advances(35), Lung Cancer Research Studies(27), Neuroblastoma Research and Treatments(21), Pancreatic and Hepatic Oncology Research(9), Cardiac, Anesthesia and Surgical Outcomes(5)

Publications103 total

Genetic attenuation of <scp>ALDH1A1</scp> increases metastatic potential and aggressiveness in colorectal cancer
Molecular Oncology·2026Open Access
Establishment of a metastatic patient-derived xenograft model of breast carcinoma
Neoplasma·2025Open Access
Increase in calcidiol level is associated with improved sternal bone healing after cardiac surgery with sternotomy—REINFORCE-D trial results
Trials·2025Open Access
The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms
European Journal of Cancer·2022· 32 cited
Vitamin D for prevention of sternotomy healing complications: REINFORCE-D trial
Trials·2020· 3 citedOpen Access
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
Endocrine·2020· 78 citedOpen Access
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
Anti-Cancer Drugs·2020· 8 citedOpen Access
Expression of molecules of the Wnt pathway and of E‑cadherin in the etiopathogenesis of human thymomas
Oncology Letters·2020· 8 citedOpen Access
Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patients—The ENETS registry.
Journal of Clinical Oncology·2018· 5 cited
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Neuroendocrinology·2018· 54 cited
Supplementary Material for: Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Figshare·2018Open Access
Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension
Annals of Oncology·2017· 2 citedOpen Access
Thymomas and thymic carcinomas
Onkologie·2017· 3 citedOpen Access
Symptomatic occlusion of mesenteric vein solved by implantation of self-expanding stent
Česká radiologie·2017Open Access
Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study.
Journal of Clinical Oncology·2017· 16 cited
The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.
Journal of Clinical Oncology·2017· 10 cited
Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE)
Annals of Oncology·2016Open Access
P-245 Growing incidence of pancreatic neuroendocrine tumours (PNET) in Czech Republic
Annals of Oncology·2016Open Access
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Endocrine Related Cancer·2016· 233 citedOpen Access
Merkel Cell Carcinoma - Epidemiology Data from the Czech National Cancer Registry
2016
page 1 of 6Next →

Frequent Co-authors

Jarosław B. Ćwikła(21), Guido Rindi(20), Marianne Pavel(19), Guillaume Cadiot(18), Philippe Ruszniewski(18), Martyn Caplin(17), Edward M. Wolin(17), Jaume Capdevila(17), Lucy Wall(17), Alexandria T. Phan(16), Edda Gomez-Panzani(13), Markus Raderer(10), Alison Langley(10), Markus Raderer(8), Éric Raymond(4), Bertram Wiedenmann(4), Ivan Borbath(4), M. Caplin(4), A. Langley(4), Joëlle Blumberg(3)